title: [DYNAMIC OF CLINICAL, LABORATORY AND SONOGRAPHIC PARAMETERS AFTER SUCCESSFUL LITHOLITIC THERAPY AT PATIENTS WITH GALLSTONE DISEASE IN ASSOCIATION WITH METABOLIC SYNDROME].
abstract: The aim of study was to determine the leading clinical, immunological and sonographic pararneters, reflecting the efficiency of Ursodeoxycholic acid (UDCA) at the rate of 10 mg per 1 kg of body weight in the treatment of gallstone disease in patients with metabolic syndrome (MS).
  
  
  METHODS
  An assessment of clinical, biochemical immunological and sonographic parameters in 54 patients with gallstone disease associated with the metabolic syndrome before and after the six-month treatment UDCA were made.
  
  
  RESULTS
  In accordance with our results the significant predictors, reflecting successful litholitic therapy at patients with gallstone disease in association with metabolic syndrome are decrease the serum concentration of gamma-glutamyltranspeptidase (P = 0.003), matrix metalloproteinase-9 (P = 0.001), increase the serum concentration of tissue inhibitor of metalloproteinases-1 (P = 0.02), decrease the left liver lobe thickness (P = 0,003) and the thickness of gallbladder wall (P = 0.0002).
  
  
  CONCLUSIONS
  The results of our study have shown that the therapy with ursodesoxycholic acid of patients with metabolic syndrome leads to decrease of factors of gallstone progression (elevated levels of gamma-glutamyltranspeptidase, matrix metalloproteinase-9 and increased thickness of the left lobe liver and gallbladder wall).
authors.forename: O V
authors.initials: OV
authors.lastname: Gaus
authors.forename: V A
authors.initials: VA
authors.lastname: Akhmedov
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D042882:Gallstones / Q000097:blood / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood / Q000276:immunology; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology; D008875:Middle Aged; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood / Q000276:immunology; D014463:Ultrasonography; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage*; D005723:gamma-Glutamyltransferase / Q000097:blood / Q000276:immunology
chemical_list: C560822:TIMP1 protein, human; D019715:Tissue Inhibitor of Metalloproteinase-1; D014580:Ursodeoxycholic Acid; D005723:gamma-Glutamyltransferase; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9